Rain Therapeutics scores $63m Series B

Newark, California-based Rain Therapeutics Inc, a biotechnology company focused on targeted therapies for patients with cancer, has secured $63 million in Series B financing.

Newark, California-based Rain Therapeutics Inc, a biotechnology company focused on targeted therapies for patients with cancer, has secured $63 million in Series B financing. The investors included Boxer Capital, Cormorant Asset Management, Samsara BioCapital, Janus Henderson Investors, Logos Capital, BVF Partners LP and Perceptive Advisors.

Source: Press Release